文献速递肝病消化道肿瘤与早癌

慢性乙型肝炎患者抗病毒治疗期间丙氨酸氨基转移酶正常与肝脏事件风险降低相关

Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.
PubMed 文献 · J Hepatol · 2018-01-01

该研究纳入2005-2016年接受恩替卡韦和/或富马酸替诺福韦二吡呋酯治疗的全港慢性乙型肝炎队列,共21,182例患者,随访4.0±1.7年。治疗12个月时ALT正常者较未正常者复合肝脏事件风险降低(校正HR 0.51,95%CI 0.42-0.61),6年累积发生率3.51% vs 5.70%。

要点

  • 治疗12个月ALT正常者复合肝脏事件风险较未正常者降低(校正HR 0.51,95%CI 0.42-0.61)。
  • ALT正常组6年复合肝脏事件累积发生率为3.51%,未正常组为5.70%(p<0.001)。
  • 治疗3、6、9、12个月ALT正常均与肝脏事件风险降低相关(校正HR 0.61至0.51)。

核心结论

  • 慢性乙型肝炎患者接受核苷(酸)类似物治疗期间ALT正常与肝脏事件风险降低相关,并转化为临床结局改善。

研究设计与样本

  • 全港队列研究,纳入2005-2016年接受恩替卡韦和/或富马酸替诺福韦二吡呋酯治疗的慢性乙型肝炎患者21,182例,随访4.0±1.7年。

主要发现

  • 治疗12个月时ALT正常者10,437例,未正常者10,745例;两组基线ALT分别为58 vs 61 U/L,HBV DNA分别为4.9 vs 5.1 log10 IU/ml,肝硬化比例分别为8.8% vs 10.5%。
  • 共627例(3.0%)发生复合肝脏事件(含肝细胞癌)。
  • 治疗3、6、9、12个月ALT正常者较未正常者的校正HR(95%CI)分别为0.61(0.49-0.77)、0.55(0.45-0.67)、0.54(0.44-0.65)、0.51(0.42-0.61),均p<0.001。
  • 6年复合肝脏事件累积发生率(95%CI)ALT正常组为3.51%(3.06%-4.02%),未正常组为5.70%(5.15%-6.32%),p<0.001。

关键数值与推荐

  • 治疗期间ALT正常定义为男性ALT<30 U/L、女性ALT<19 U/L。
  • 排除抗病毒治疗前或治疗第一年内发生肝脏事件者,以及随访<1年者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Recent studies reveal that the rate of normal on-treatment alanine aminotransferase (ALT) appears different for different nucleos(t)ide analogues (NAs); yet its clinical significance is unclear. We aimed to evaluate the impact of normal on-treatment ALT during antiviral treatment with entecavir (ETV) or tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB). METHODS: A territory-wide cohort of patients with CHB who received ETV and/or TDF in 2005-2016 was identified. Serial on-treatment ALT levels were collected and analyzed. Normal on-treatment ALT (ALT-N) was defined as ALT <30 U/L in males and <19 U/L in females. The primary and secondary outcomes were composite hepatic events (including hepatocellular carcinoma) based on diagnostic codes. Patients with hepatic events before or during the first year of antiviral treatment or follow-up <1 year were excluded. RESULTS: A total of 21,182 patients with CHB (10,437 with and 10,745 without ALT-N at 12 months after antiviral treatment) were identified and followed for 4.0 ± 1.7 years. Patients with and without ALT-N differed in baseline ALT (58 vs. 61 U/L), hepatitis B virus DNA (4.9 vs. 5.1 log10 IU/ml) and cirrhosis status (8.8% vs. 10.5%). A total of 627 (3.0%) patients developed composite hepatic events. Compared to no ALT-N, ALT-N at 3, 6, 9 and 12 months reduced the risk of hepatic events, after adjustment for baseline ALT and other important covariates, with adjusted hazard ratios (95% CI) of 0.61 (0.49-0.77), 0.55 (0.45-0.67), 0.54 (0.44-0.65) and 0.51 (0.42-0.61) respectively (all p <0.001). The cumulative incidence (95% CI) of composite hepatic events at six years was 3.51% (3.06%-4.02%) in ALT-N and 5.70% (5.15%-6.32%) in the no ALT-N group (p <0.001). CONCLUSIONS: Normal on-treatment ALT is associated with a lower risk of hepatic events in patients with CHB receiving NA treatment, translating into improved clinical outcomes in these patients. LAY SUMMARY: We investigated 21,182 patients with chronic hepatitis B receiving antiviral treatment. Alanine aminotransferase is a laboratory marker of liver function, with raised levels indicating liver dysfunction and in severe cases hepatitis. Normal on-treatment alanine aminotransferase during the first year of treatment in patients with CHB is associated with a lower risk of hepatic events.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Wong GL, Chan HL, Tse YK, et al. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. J Hepatol. 2018. PMID: 29758335. doi:10.1016/j.jhep.2018.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。